If your organization isn’t prepared, the risks are clear: fines, compliance penalties, reputational harm, and provider dissatisfaction. 

At MRIoA, our mission is to give health plans clarity and confidence in navigating these complex changes. Here’s a closer look at four states where new regulations are going into effect and what they mean for your business. 

Georgia – H.B. 197 (Effective Jan 1, 2026) 

What’s changing: Georgia requires insurers to make a good-faith effort for a pre-denial peer-to-peer review. That effort must include either a callback system, a telecommunications platform, or a public website to schedule callbacks. In addition, insurers must implement and maintain a program to reduce prior authorization requirements, with the first filing due July 1, 2026.  

• Georgia General Assembly – HB 197: https://www.legis.ga.gov/legislation/64277 

Why it matters: These requirements add new operational and reporting burdens. Failure to comply risks fines, member delays, and strained provider relationships. 

Takeaway: Don’t wait until the deadline. Begin building callback workflows now and assess how your PA program can be reduced without compromising compliance. 

Illinois – H.B. 4055 (Effective Jan 1, 2026) 

What’s changing: Illinois will restrict plans from requiring prior authorization for FDA-approved therapies for hereditary bleeding disorders more frequently than every six months, or for the length of the prescription, whichever is shorter.  

• Illinois General Assembly – HB4055: https://www.ilga.gov/legislation/billstatus.asp?DocNum=4055&GAID=19&GA=103&DocTypeID=HB&LegID=152792&SessionID=112 

Why it matters: This is not a full PA ban, but it requires significant adjustments to authorization logic and systems. Failure to comply risks penalties, reputational harm, and potential patient impact. 

Takeaway: Update your PA rules and test your systems now to avoid costly mistakes. 

Texas – H.B. 3812 & S.B. 815 (Effective Sept 1, 2025) 

What’s changing: H.B. 3812 requires that certain determinations be made by a Texas-licensed physician, who may not hold an administrative medicine license. 

• Texas Legislature – HB 3812: https://capitol.texas.gov/BillLookup/History.aspx?LegSess=88R&Bill=HB3812 

S.B. 815 prohibits utilization review agents from using automated decision systems to make adverse determinations. The law also grants the commissioner authority to audit UR agents’ practices.  

• Texas Legislature – SB 815: https://capitol.texas.gov/BillLookup/History.aspx?LegSess=88R&Bill=SB815 

Why it matters: Health plans must align physician oversight models with licensing requirements and ensure compliance processes can withstand audits. 

Takeaway: Evaluate your current utilization review oversight and ensure your staffing and governance models meet Texas’ new requirements. 

The Bottom Line 

These are not minor updates. They are business-impacting regulatory changes with real financial, operational, and reputational stakes. 

MRIoA provides the clinical expertise, regulatory guidance, and actionable insights that health plans, TPAs, and PBMs need to adapt quickly and with confidence. 

Join us for the Regulatory & Compliance Roundtable on October 2, 2025 to hear from experts, understand what these laws mean for your organization, and walk away with strategies to reduce risk and ensure compliance. 

View the Roundtable Recording

The post Is your Organization Ready for Fall 2025 State Regulatory Changes?  appeared first on MRIoA.

According to the American Medical Association, ten states passed significant prior authorization reforms in 2024, tightening turnaround times, mandating greater transparency, and easing administrative burdens. At the same time, nine states and the District of Columbia passed reforms in the prior year, and nearly 30 states are considering similar legislation now.  

This wave of legislation is fundamentally changing how health plans, TPAs, and PBMs will be evaluated and held accountable. Non-compliance is no longer measured only in fines, but in lost revenue, reputational damage, and competitive disadvantage.  

Why These Changes Matter to the C-Suite 

Revenue at Risk 
Fines, lawsuits, and contract losses can dwarf the cost of proactive compliance. Illinois’ new restrictions on prior authorization for hereditary bleeding disorder drugs require precise operational updates. A missed adjustment is not just a workflow error. It is a potential revenue and reputation crisis. 

Operational Disruption 
Georgia’s H.B. 197 mandates callback systems and PA-reduction programs. That means new infrastructure, new processes, and new reporting obligations. For executives, this translates into resourcing decisions and system investments that must be made quickly. 

Regulatory Scrutiny 
Texas’ new laws (S.B. 815 and H.B. 3812) create strict requirements for utilization review oversight and give regulators the authority to audit payer processes at any time. That puts executive accountability squarely in the spotlight. 

Competitive Differentiation 
New Jersey’s A.B. 1825 establishes step therapy exception requirements that will create winners and losers. Those who adapt quickly will maintain provider trust and member satisfaction. Those who lag risk being viewed as slow, opaque, and non-compliant. That is a costly brand position in a competitive market. 

What Executives Should Be Asking 

• Where is our greatest compliance risk exposure: financial, operational, or reputational? 
• Do we have the infrastructure to meet callback, exception, and reporting mandates across multiple states? 
• How are we monitoring and auditing utilization review processes to ensure readiness for regulator scrutiny? 
• Are we positioned to turn compliance into an advantage, not just an obligation? 

MRIoA’s Role: From Compliance Burden to Strategic Readiness 

For leadership, the question is not just “are we compliant?” It is “how do we make compliance an advantage?” 

MRIoA helps executives answer that question by delivering: 

• Regulatory Foresight – We track and interpret state-by-state changes before they become pain points, giving leadership the ability to plan strategically instead of reactively. 
• Operational Assurance – With the largest state-matched reviewer network in the nation, we ensure compliance requirements do not stall operations, disrupt provider relations, or inflate costs. 
• Business Intelligence – Our analytics surface where regulatory risk lives in your workflows, allowing you to redirect resources, reduce waste, and protect revenue. 

MRIoA does not just reduce the burden of compliance. We give executives the clarity and confidence to make faster, better, and more defensible business decisions. 

The Strategic Imperative 

The regulatory landscape is not slowing down. With dozens of states advancing new prior authorization reforms in 2024 and 2025, compliance is now a C-suite responsibility. It is no longer about avoiding penalties. It is about protecting revenue, sustaining trust, and creating competitive advantage. 

Watch MRIoA’s Regulatory & Compliance Roundtable from October 2, 2025. Gain insights into what these state laws mean for your organization and learn how to turn regulatory change into strategic readiness. 

Vide the Roundtable Recording

The post Compliance Is a Business Risk You Can’t Ignore  appeared first on MRIoA.